KALETRA in Combination With New Substances (PROTEKT)
Phase of Trial: Phase IV
Latest Information Update: 25 May 2017
At a glance
- Drugs Lopinavir/ritonavir (Primary)
- Indications HIV infections
- Focus Adverse reactions
- Acronyms PROTEKT
- Sponsors Abbott Laboratories; AbbVie
- 07 Jun 2017 Biomarkers information updated
- 04 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 08 Jan 2016 Planned End Date changed from 1 Oct 2017 to 1 Jan 2016 as reported by ClinicalTrials.gov.